Homology Medicines Inc
NASDAQ:FIXX
Intrinsic Value
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. [ Read More ]
The intrinsic value of one FIXX stock under the Base Case scenario is 0.1693 USD. Compared to the current market price of 0.9347 USD, Homology Medicines Inc is Overvalued by 82%.
Valuation Backtest
Homology Medicines Inc
Run backtest to discover the historical profit from buying and selling FIXX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Homology Medicines Inc
Current Assets | 83.9m |
Cash & Short-Term Investments | 82.7m |
Other Current Assets | 1.3m |
Non-Current Assets | 650k |
PP&E | 650k |
Current Liabilities | 11.6m |
Accounts Payable | 3.2m |
Accrued Liabilities | 8.3m |
Earnings Waterfall
Homology Medicines Inc
Revenue
|
1.2m
USD
|
Operating Expenses
|
-93.3m
USD
|
Operating Income
|
-92.1m
USD
|
Other Expenses
|
-20.9m
USD
|
Net Income
|
-113m
USD
|
Free Cash Flow Analysis
Homology Medicines Inc
FIXX Profitability Score
Profitability Due Diligence
Homology Medicines Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
Score
Homology Medicines Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
FIXX Solvency Score
Solvency Due Diligence
Homology Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Homology Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FIXX Price Targets Summary
Homology Medicines Inc
According to Wall Street analysts, the average 1-year price target for FIXX is 1.5 USD .
Ownership
FIXX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FIXX Price
Homology Medicines Inc
Average Annual Return | -46.68% |
Standard Deviation of Annual Returns | 28.37% |
Max Drawdown | -98% |
Market Capitalization | 54.2m USD |
Shares Outstanding | 58 133 500 |
Percentage of Shares Shorted | 0.04% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. The company is headquartered in Bedford, Massachusetts and currently employs 224 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.
Contact
IPO
Employees
Officers
The intrinsic value of one FIXX stock under the Base Case scenario is 0.1693 USD.
Compared to the current market price of 0.9347 USD, Homology Medicines Inc is Overvalued by 82%.